Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
SYDNEY,Aug. 22,2024-- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"),a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment o